AG
ZNTL icon

Algert Global’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Algert Global’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-48,496
Closed -$65K – 1360
2025
Q4 		$65K Hold
48,496
– – ﹤0.01% 1111
2025
Q3 		$73K Buy
+48,496
New +$72.7K ﹤0.01% 1099
2025
Q2 		– Sell
-122,348
Closed -$195K – 1371
2025
Q1 		$195K Buy
122,348
+71,248
+139% +$154K ﹤0.01% 1088
2024
Q4 		$155K Sell
51,100
-22,000
-30% -$72.1K ﹤0.01% 1095
2024
Q3 		$269K Buy
73,100
+53,981
+282% +$196K 0.01% 1021
2024
Q2 		$78K Buy
+19,119
New +$214K ﹤0.01% 1417
2024
Q1 		– Sell
-33,350
Closed -$505K – 1303
2023
Q4 		$505K Buy
+33,350
New +$487K 0.02% 819

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Algert Global's ZNTL Position: Q1 2026 in Review

Algert Global sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2026, closing a stake of 48,496 shares — an estimated $65K sold.

Algert Global first reported a position in ZNTL in Q4 2023 and held it in 7 quarters. The position peaked at $505K in Q4 2023. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Algert Global reported no remaining Zentalis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Algert Global sold 48,496 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $65K.
  • Algert Global first reported a position in Zentalis Pharmaceuticals in Q4 2023 and held it in 7 quarters.
  • Algert Global's Zentalis Pharmaceuticals position peaked at $505K in Q4 2023.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Algert Global's 13F filing for Q1 2026, filed 14 May 2026.